文献速递前列腺癌

美国西班牙裔前列腺癌差异与来源国相关:基于SEER的人群分析

Prostate cancer disparities in Hispanics by country of origin: a nationwide population-based analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-10-02

基于SEER 1995–2014年72,134例西班牙裔前列腺癌患者,按来源国分层比较诊断特征与生存。墨西哥裔诊断时分期更晚、PSA更高、Gleason评分更高,古巴裔与多米尼加裔诊断时肿瘤更有利;中位随访69个月后,相比墨西哥裔,古巴裔与波多黎各裔总生存更差,多米尼加裔、中南美裔及来源未注明者前列腺癌生存更好。

要点

  • 西班牙裔前列腺癌特征与生存因来源国不同而存在差异。
  • 墨西哥裔诊断时分期更晚、PSA与Gleason评分更高。
  • 相比墨西哥裔,多米尼加裔与中南美裔前列腺癌生存更好。

核心结论

  • 在美国西班牙裔中,前列腺癌特征与生存按来源国存在差异,多米尼加裔、中南美裔及西班牙裔来源未注明者相比墨西哥裔、古巴裔与波多黎各裔前列腺癌生存更好。

研究设计与样本

  • 回顾性分析SEER项目1995–2014年72,134例成年西班牙裔前列腺癌患者,来源国按SEER编码分组。
  • 来源国分布:墨西哥裔16,995例(24%)、中南美裔6949例(10%)、波多黎各裔3582例(5%)、古巴裔2587例(4%)、多米尼加裔725例(1%)、来源未注明41,296例(57%)。
  • 采用卡方检验与Kruskal-Wallis检验分析患者与肿瘤特征,采用Kaplan-Meier与校正基线变量的Cox模型分析总生存与前列腺癌生存。

主要发现

  • 诊断时墨西哥裔分期更晚、PSA更高、Gleason评分更高,古巴裔与多米尼加裔诊断时前列腺癌更有利(均P<0.05)。
  • 中位随访69个月,20,317例死亡,其中6,223例为前列腺癌死亡。
  • 相比墨西哥裔,古巴裔总生存更差(HR=1.22,95%CI=[1.14-1.30]),波多黎各裔总生存更差(HR=1.15 [1.08-1.22])。
  • 相比墨西哥裔,多米尼加裔(HR=0.76 [0.64-0.91])、中南美裔(HR=0.68 [0.65-0.72])与来源未注明者(HR=0.81 [0.78-0.84])总生存更好。
  • 相比墨西哥裔,古巴裔(HR=1.08 [0.96-1.22])与波多黎各裔(HR=1.03 [0.92-1.15])前列腺癌生存相近,多米尼加裔(HR=0.72 [0.53-0.98])、中南美裔(HR=0.67 [0.60-0.74])与来源未注明者(HR=0.68 [0.64-0.73])前列腺癌生存显著更好。

临床怎么用

  • 评估美国西班牙裔前列腺癌患者风险与预后时应考虑来源国背景,而非将其视为同质群体。
  • 对墨西哥裔、古巴裔与波多黎各裔患者可关注更晚分期或更差生存的潜在风险,加强个体化随访。

局限性

  • 为基于SEER的回顾性分析,来源国依赖SEER编码,57%为来源未注明。
  • 原文未报告具体局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We sought to evaluate prostate cancer (PCa) characteristics and outcomes of Hispanics living in the United States by country of origin in the Surveillance, Epidemiology and End Results (SEER) program. METHODS: Retrospective analysis of 72,134 adult Hispanics with PCa between 1995 and 2014. Origin was Mexican (N = 16,995; 24%), South/Central American (N = 6949; 10%), Puerto Rican (N = 3582; 5%), Cuban (N = 2587; 4%), Dominican (N = 725; 1%), Hispanic not specified (NOS, N = 41,296; 57%), as coded by SEER. Patient and PCa characteristics were analyzed with chi-square and Kruskal-Wallis tests. Overall and PCa survival were analyzed with Kaplan-Meier and Cox models adjusting for baseline variables. RESULTS: At diagnosis, Mexicans had more advanced stage, higher prostate-specific antigen, and higher Gleason score while Cubans and Dominicans had more favorable PCa at diagnosis (all P < 0.05). After a median follow-up of 69 months, 20,317 men died, including 6223 PCa deaths. Compared to Mexicans, Cubans (HR = 1.22, 95% CI = [1.14-1.30]) and Puerto Ricans (HR = 1.15 [1.08-1.22]) had worse overall survival while Dominicans (HR = 0.76 [0.64-0.91]), South/Central Americans (HR = 0.68 [0.65-0.72]), and NOS (HR = 0.81 [0.78-0.84]) had better overall survival. Compared to Mexicans, Cubans (HR = 1.08 [0.96-1.22]) and Puerto Ricans (HR = 1.03 [0.92-1.15]) had similar PCa survival while Dominicans (HR = 0.72 [0.53-0.98]), South/Central Americans (HR = 0.67 [0.60-0.74]), and NOS (HR = 0.68 [0.64-0.73]) had significantly better PCa survival. CONCLUSIONS: Among Hispanics in the United States, disparities in PCa characteristics and survival by country of origin exist, with Dominicans, South/Central Americans, and Hispanic NOS having better PCa survival compared to Mexicans, Cubans, and Puerto Ricans.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Dobbs RW, Malhotra NR, Abern MR, et al. Prostate cancer disparities in Hispanics by country of origin: a nationwide population-based analysis. Prostate Cancer Prostatic Dis. 2018. PMID: 30279578. doi:10.1038/s41391-018-0097-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。